Pilot Study of a Commercialized Human Papillomavirus (HPV) Genotyping Assay: Comparison of HPV Risk Group to Cytology and Histology-Reference-Cited by-同舟云学术

Pilot Study of a Commercialized Human Papillomavirus (HPV) Genotyping Assay: Comparison of HPV Risk Group to Cytology and Histology

Published:2006-11 Issue:11 Volume:44 Page:3915-3917
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Castle Philip E.¹,Sadorra Mark²,Garcia Francisco³,Holladay E. Blair⁴,Kornegay Janet²

Affiliation:

1. Division of Cancer Epidemiology, National Cancer Institute, NIH, DHHS, Bethesda, Maryland

2. Roche Molecular Systems, Alameda, California

3. University of Arizona Health Sciences Center, Tucson, Arizona

4. Medical University of South Carolina, Charleston, South Carolina

Abstract

ABSTRACT We evaluated a commercialized PCR assay, Linear Array, that detects 37 human papillomavirus (HPV) genotypes, using a sample of liquid cytology specimens ( n = 534). We found a strong association of an increasing level of HPV risk (HPV type 16 [HPV16] > HPV18 > other carcinogenic types > noncarcinogenic types > negative specimens) with increasing severities of cytologic interpretations ( P Trend < 0.0005) and histologic diagnoses ( P Trend < 0.0005).

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01305-06

Reference15 articles.

1. Bulk, S., J. Berkhof, N. W. Bulkmans, G. D. Zielinski, L. Rozendaal, F. J. van Kemenade, P. J. Snijders, and C. J. Meijer. 2006. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br. J. Cancer94:171-175.

2. Bulkmans, N. W., M. C. Bleeker, J. Berkhof, F. J. Voorhorst, P. J. Snijders, and C. J. Meijer. 2005. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int. J. Cancer117:177-181.

3. Castle, P. E., M. Schiffman, R. D. Burk, S. Wacholder, A. Hildesheim, R. Herrero, M. C. Bratti, M. E. Sherman, and A. Lorincz. 2002. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev.11:1394-1399.

4. Clifford, G. M., S. Gallus, R. Herrero, N. Munoz, P. J. Snijders, S. Vaccarella, P. T. Anh, C. Ferreccio, N. T. Hieu, E. Matos, M. Molano, R. Rajkumar, G. Ronco, S. de Sanjose, H. R. Shin, S. Sukvirach, J. O. Thomas, S. Tunsakul, C. J. Meijer, and S. Franceschi. 2005. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet366:991-998.

5. Cogliano, V., R. Baan, K. Straif, Y. Grosse, B. Secretan, and F. El Ghissassi. 2005. Carcinogenicity of human papillomaviruses. Lancet Oncol.6:204.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of other high-risk HPV types on cervical intraepithelial neoplasia and cancer;European Journal of Gynaecological Oncology;2022

2. Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: A large population-based study;Gynecologic Oncology;2019-12

3. Exploration of the effect of human papillomavirus (HPV) vaccination in a cohort of pregnant women in Montreal, 2010–2016;Heliyon;2019-08

4. Human papillomavirus (HPV) perinatal transmission and risk of HPV persistence among children: Design, methods and preliminary results of the HERITAGE study;Papillomavirus Research;2016-12

5. Performance of HPV E6/E7 mRNA Genotyping Test on Paired Cervical Cancer Exfoliated Cells and Formalin Fixed Paraffin Embedded Tissues;Biomedical Science Letters;2016-09-30